tirzepatide for ckd GLP therapies have established themselves as kidney-protective in type 2 diabetes and high risk of kidney disease. This new post-hoc analysis of SURPASS-CVOT's kidney outcomes shows greater kidney protection with (#mounjaro) SURPASS-4: Tirzepatide slows kidney disease

Here is what the medication is, how local availability differs from telehealth Retatrutides phase 2 trial produced an average of about 24% body weight loss, higher than the numbers seen with approved medications like tirzepatide and semaglutide

The most commonly reported side effects include: Nausea Mild stomach discomfort Constipation Diarrhea Reduced appetite These symptoms are typically mild to moderate and often occur during the early stages of treatment or when increasing the dosage

DISCUSSION Obesity is on track to become the primary preventable risk factor of various morbidities including cardiovascular disease and cancer, so early targeted treatment and management of obesity is essential

2024;47:e17

This guide breaks down exactly what every formulation of tirzepatide should look like, what each color means, and when a color change means you need to throw the vial away

The first concern is overlapping nausea